AlphAIAlphAI — Financial news for AI agents
tipranks.com$LQDA

Liquidia Reports Strong Third-Quarter YUTREPIA Sales Growth

Liquidia (LQDA) reported Q3 2026 net sales of $222.7M for YUTREPIA, up 31% from Q2, with October patient shipments at a record high. The company settled litigation with United Therapeutics, incurring a $389.7M charge and a Q3 net loss of $236.3M. Non-GAAP adjusted EBITDA was $140.5M, up for the fifth consecutive quarter. Cash reserves were $396.1M at Q3's end. The FDA granted Fast Track designation to YUTREPIA for a new indication, and the company initiated two new studies.

Original reporting
tipranks.com
Published Nov 10, 2026, 12:36 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 12:52 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$LQDA
Neutral
high confidence
Mentioned
$LQDA
Relevance
7/10
AlphAI data visualization · based on tipranks.com
Decision brief

The 30-second read

$LQDANeutralMed
01

Why it matters

Q3 sales growth and a new Fast Track designation suggest long‑term growth, but the $389.7M settlement charge and net loss introduce near‑term downside risk.

02

Market read

First‑report earnings and settlement data provide fresh material for traders; the mixed signal may prompt short‑term positioning.

03

What to watch

Fast Track designation for YUTREPIA may drive future upside beyond the current quarter.

Relevance 7/10Novelty 7/10Timing: today

Background

Liquidia Technologies (LQDA) is a biopharma developing inhaled treatments for respiratory and vascular diseases.

Company-level read

Ticker impact

$LQDANeutralHigh confidence
Context

Liquidia reported Q3 net product sales of $222.7M for YUTREPIA, a 31% QoQ increase, and disclosed a $389.7M litigation settlement charge.

Expected impact

potential short-term pressure as the market prices in the settlement charge despite sales growth

Evidence & confidence

Sales growth is positive, yet the sizable one‑time charge and net loss create uncertainty about near‑term earnings.

Market effects

Sector

Highlights continued demand for inhalation therapies in respiratory disease, may benefit peers in biotech respiratory space.

Regional

US biotech sector sees mixed reaction; settlement underscores litigation risk in pharma.

Global

Limited to investors tracking US‑listed biotech firms.

Counterpoint

What could challenge this read

The settlement charge could be a one‑off event, allowing the stock to rally on the sales momentum.

Key entities

  • company
    Liquidia Technologies

    US‑listed biopharma developing YUTREPIA inhalation powder.

  • company
    United Therapeutics

    Counterparty in the global settlement with Liquidia.

Read at source← All news

StoryLiquidia posts strong Q3 sales and adjusted EBITDA growth, but GAAP loss driven by $389.7M settlement charge

Also covered by

4 outlets

Related articles

$LQDAMedAI 8/10

Why is Liquidia stock gaining today?

Liquidia Corporation (LQDA) shares rose 1.4% in pre-market trading after reporting Q3 2026 results. Revenue of $225.3M beat estimates, driven by $222.7M in YUTREPIA sales, up 31% from the prior quarter. A $389.7M litigation charge resulted in a GAAP net loss of $2.64 per share, but operational metrics showed growth, including record patient shipments and an expanding prescriber base. The company's cash position increased to $396.1M.

investing.com
$LQDAHighAI 8/10

Liquidia Corporation Reports Third Quarter 2026 Financial Results

Liquidia Corp (LQDA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Liquidia Corporation Reports Third Quarter 2026 Financial Results · YUTREPIA® (treprostinil) inhalation powder net product sales of $222.7 million in the third quarter of 2026, up 31% from the second quarter of 2026 · October 2026 total patient shipments reached thei

SEC EDGAR 8-K